False: Covishield vaccine is likely to produce more antibodies than Covaxin.

There is no peer-reviewed scientific evidence to compare Covishield and Covaxin's efficacy in producing COVID-19 antibodies. A study published by Indian doctors compared the response rate of Covishield and Covaxin among health care workers(HCW). It shows that both vaccines elicited a good immune response after two doses. After two doses of both vaccines, 95 percent of the 515 HCW (305 male, 210 female) were seropositive. Four hundred twenty-five subjects received Covishield, and ninety people received Covaxin. In addition, both vaccine receivers experienced mild to moderate adverse reactions, and none had severe or unexpected side effects. The study is not peer-reviewed yet. According to the Indian Ministry of Health and Family Welfare, there is no direct comparison between the two vaccines used in the country. Both are effective in preventing infection and a person's sickness from progressing to a severe stage. On May 20, 2021, the Press Information Bureau (PIB) posted a tweet stating that there is no direct scientific comparison between the two vaccines. "Both work well in preventing the infection as well as in preventing severe illness," the tweet said. In May 2021, media reports said that the Indian Council of Medical Research (ICMR) started a project to measure the real-world effectiveness of Covishield and Covaxin. The study will compare the vaccination statuses of nearly 1,300 hospitalized severe COVID-19 patients with around 2,600 persons who are found COVID-19 negative in tests. The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19, including symptoms, prevention, and available treatment, please refer to the World Health Organization or your national healthcare authority.